The Amyotrophic lateral sclerosis (ALS) Pipeline report embraces in-depth commercial and clinical assessment of the Amyotrophic lateral sclerosis (ALS) pipeline products from the pre-clinical developmental phase to the marketed phase.
The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Amyotrophic lateral sclerosis (ALS) collaborations, licensing, mergers, and acquisition, funding, designations, and other product-related details.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight
The dynamics of the Amyotrophic lateral sclerosis (ALS) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also the expected launch of emerging therapies during the forecasted period.
Amyotrophic lateral sclerosis (ALS) companies:
Cytokinetics
Orion Pharma
Brainstorm Cell Therapeutics
Biogen
AB Science
Ionis Pharmaceuticals
Clene Nanomedicine
Neurosense therapeutics
Amylyx
MediciNova
Biohaven Pharmaceuticals
Prilenia Therapeutics
And many others.
Amyotrophic lateral sclerosis (ALS) therapies covered in the report include:
ODM-109
Arimoclomol
Reldesemtiv
Verdiperstat
NurOwn
IC14
BIIB067
CNM-Au8
And many more.
Amyotrophic lateral sclerosis (ALS) Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights about companies that are developing therapies for the treatment of Amyotrophic lateral sclerosis (ALS) with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the Amyotrophic lateral sclerosis (ALS) treatment.
-
Amyotrophic lateral sclerosis (ALS) key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Amyotrophic lateral sclerosis (ALS) Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Amyotrophic lateral sclerosis (ALS) market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Scope of the report
-
The Amyotrophic lateral sclerosis (ALS) Pipeline Report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Amyotrophic lateral sclerosis (ALS) across the complete product development cycle, including all clinical and non-clinical stages.
-
It comprises detailed profiles of Amyotrophic lateral sclerosis (ALS) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
-
Detailed research and development progress and clinical trial of Amyotrophic lateral sclerosis (ALS), results wherever available, are also included in the pipeline study.
-
Coverage of dormant and discontinued pipeline projects along with the reasons if available across Amyotrophic lateral sclerosis (ALS).
Report Highlights
-
A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Amyotrophic lateral sclerosis (ALS).
-
In the coming years, the Amyotrophic lateral sclerosis (ALS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
-
The companies and academics are working to assess challenges and seek opportunities that could influence Amyotrophic lateral sclerosis (ALS) Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.
-
A detailed portfolio of major pharma players who are involved in fueling the Amyotrophic lateral sclerosis (ALS) treatment market. Several potential therapies for Amyotrophic lateral sclerosis (ALS) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Amyotrophic lateral sclerosis (ALS) market size in the coming years.
-
Our in-depth analysis of the Amyotrophic lateral sclerosis (ALS) pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Table of Content
1. Report Introduction
2. Amyotrophic lateral sclerosis (ALS)
3. Amyotrophic lateral sclerosis (ALS) Current Treatment Patterns
4. Amyotrophic lateral sclerosis (ALS) - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Amyotrophic lateral sclerosis (ALS) Late Stage Products (Phase-III)
7. Amyotrophic lateral sclerosis (ALS) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Amyotrophic lateral sclerosis (ALS) Discontinued Products
13. Amyotrophic lateral sclerosis (ALS) Product Profiles
14. Amyotrophic lateral sclerosis (ALS) Key Companies
15. Amyotrophic lateral sclerosis (ALS) Key Products
16. Dormant and Discontinued Products
17. Amyotrophic lateral sclerosis (ALS) Unmet Needs
18. Amyotrophic lateral sclerosis (ALS) Future Perspectives
19. Amyotrophic lateral sclerosis (ALS) Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Related Reports
Amyotrophic lateral sclerosis (ALS) Market Insight
DelveInsight's "Amyotrophic lateral sclerosis (ALS) Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the ALS historical and forecasted epidemiology as well as the Amyotrophic lateral sclerosis (ALS) market size and share analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
Amyotrophic lateral sclerosis (ALS) Epidemiology Forecast
DelveInsight's Amyotrophic lateral sclerosis (ALS) - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Amyotrophic lateral sclerosis (ALS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Latest BioPharma Blogs - Rare Disease Market Drivers
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
